Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

Phase

N/A

Condition

Pancreatitis

Pancreatic Disorders

Treatment

RELiZORB™

ReliZORB™

Placebo

Clinical Study ID

NCT05710315

INOVA-2023-42

Ages 18-89
All Genders

Study Summary

The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion.

RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in patients 5 years of age or older. While the use of RELiZORB™ in this study is consistent with the FDA approval, the use of RELiZORB™ in patients with multi organ failure is not in the current standard of care practice at Inova Health Care facilities.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female patients aged 18 - 89 years of age.
Patients who have Multi-Organ Failure (MOF) (defined as requiring mechanicalventilation and demonstrating at least one more system failure on the SOFA score onthe day of ICU admission).
Patients who have not yet been initiated on enteral nutrition, yet enteralnutritional support is needed, or patients who have been initiated on enteralnutrition within the previous 48 hours. Enteral nutrition support defined as supportplanned to be given via any route connected to the gastrointestinal system (i.e.,the enteral route). This includes tube feeding using nasogastric, nasoduodenal,gastrostomy, jejunostomy tubes, or similar.
Patients who lack the capacity to consent for themselves may be included uponreceiving consent from their legally authorized representatives.

Exclusion

Exclusion Criteria:

Pregnant women and prisoners.
Hypotension is attributed to suspected or confirmed cardiogenic shock.
Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation,fistulas or tract discontinuity, or other contraindication for enteral nutrition.
Sepsis suspected or confirmed due to an abdominal source and enteral nutrition iscontraindicated.
C. Difficile or other gastrointestinal infection that may manifest with diarrhea.
Use of pancreatic hormone stimulant or inhibitor (e.g. octreotide, pancreatic enzymesupplements) during or immediately prior to hospital admission.
Any other reason that the treating or investigator team considers to be acontraindication to enteral nutrition.

Study Design

RELiZORB™

May 07, 2025

August 31, 2026

Study Description

This is a double-blind, placebo-controlled, parallel design study. A total of 32 adult patients who have been admitted to the Surgical or Medical Intensive Care Unit with evidence of MOF (defined as requiring mechanical ventilation and demonstrating at least one more system failure on the SOFA score on the day of ICU admission) and who have not yet been initiated on enteral nutrition or were initiated on enteral nutrition up to 48 hours prior.

After informed consent has been obtained, two patients will receive enteral formula administered through RELiZORB™ as test subjects (will be excluded from analysis). Subsequently, patients will be randomized to RELiZORB™ vs placebo cartridges in a 1:1 ratio. Enteral nutrition will be administered through RELiZORB™ cartridges (up to 6 cartridges per day depending on the volume of enteral nutrition). Patients will be studied for a total of 5 days (considered to be the end of study). Patients will return to the original form of nutritional support per their routine clinical care.

Connect with a study center

Inova Fairfax Medical Campus
Falls Church, Virginia 22042
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.